Sugi Predict

Sugi Predict / Targets / ABL2

ABL2

Tyrosine-protein kinase ABL2 · P42684 · ABL2 on Sugi Atlas →

61,157 patent compounds predicted against ABL2, 48,015 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL132510 SCHEMBL132510 1.00 11/20
SCHEMBL132511 SCHEMBL132511 0.71 11/20
Imatinib Imatinib (SCHEMBL3827) 1.00 7/20
Imatinib Imatinib (SCHEMBL8217) 0.94 7/20
SCHEMBL9485 SCHEMBL9485 0.81 5/20
SCHEMBL161460 SCHEMBL161460 0.58 5/20
SCHEMBL145785 SCHEMBL145785 0.49 4/20
SCHEMBL130590 SCHEMBL130590 0.56 3/20
SCHEMBL11405 SCHEMBL11405 0.44 3/20
SCHEMBL10788 SCHEMBL10788 0.35 3/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL8226) 1.00 2/20
Bosutinib Bosutinib (SCHEMBL158390) 1.00 2/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL290515) 1.00 2/20
SCHEMBL1430 SCHEMBL1430 0.82 2/20
SCHEMBL9565 SCHEMBL9565 0.81 2/20
SCHEMBL9763 SCHEMBL9763 0.81 2/20
SCHEMBL10208 SCHEMBL10208 0.81 2/20
SCHEMBL231130 SCHEMBL231130 0.78 2/20
SCHEMBL9642 SCHEMBL9642 0.77 2/20
SCHEMBL145626 SCHEMBL145626 0.70 2/20

Clinical trials — most relevant to ABL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation PHASE4COMPLETED
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation PHASE3COMPLETED
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia PHASE3RECRUITING
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients PHASE2COMPLETED
STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia PHASE2COMPLETED
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia PHASE2WITHDRAWN
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors PHASE2ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment PHASE2UNKNOWN
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia PHASE2COMPLETED
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase PHASE2RECRUITING
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation PHASE2COMPLETED
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia PHASE2UNKNOWN
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. PHASE2COMPLETED
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP PHASE2RECRUITING
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML PHASE1RECRUITING
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL PHASE1COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Withdrawal or Reduction TKIs in CML-CP nanUNKNOWN
Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase nanUNKNOWN
Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes nanUNKNOWN
Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib nanUNKNOWN
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log nanUNKNOWN
Effect of 2nd Gen TKI in CML nanCOMPLETED
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ABL2 binder may also engage these)

ProteinNameSimilarity
Q4JIM5 — 1.000 Q4JIM5 →
P00520 — 0.996 P00520 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.995 landscape →
ABL1 Tyrosine-protein kinase ABL1 0.994 landscape →
Q9H329 — 0.993 Q9H329 →
Q924U5 — 0.993 Q924U5 →
Q3ULB5 — 0.993 Q3ULB5 →
A6QP06 — 0.993 A6QP06 →
Q5R8Z4 — 0.992 Q5R8Z4 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.992 landscape →
Q63553 — 0.992 Q63553 →
Q3U1V8 — 0.992 Q3U1V8 →
Q2PFD7 — 0.992 Q2PFD7 →
Q9P202 — 0.992 Q9P202 →
Q5R8X7 — 0.991 Q5R8X7 →
Q8VDU5 — 0.991 Q8VDU5 →
Q8IR79 — 0.991 Q8IR79 →
G5EFD2 — 0.991 G5EFD2 →
B2GUY1 — 0.991 B2GUY1 →
Q6NN85 — 0.990 Q6NN85 →
Q641K5 — 0.990 Q641K5 →
A7MBB4 — 0.990 A7MBB4 →
Q6P0Q8 — 0.990 Q6P0Q8 →
P48193 — 0.990 P48193 →
Q60700 — 0.990 Q60700 →
Q5VZ18 — 0.990 Q5VZ18 →
O95625 — 0.990 O95625 →
Q60610 — 0.990 Q60610 →
Q1LYM3 — 0.990 Q1LYM3 →
Q6DN90 — 0.990 Q6DN90 →